[go: up one dir, main page]

EA201391286A1 - Лечение солидных опухолей - Google Patents

Лечение солидных опухолей

Info

Publication number
EA201391286A1
EA201391286A1 EA201391286A EA201391286A EA201391286A1 EA 201391286 A1 EA201391286 A1 EA 201391286A1 EA 201391286 A EA201391286 A EA 201391286A EA 201391286 A EA201391286 A EA 201391286A EA 201391286 A1 EA201391286 A1 EA 201391286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
iron chelator
inhibits autophagy
chelator
possibly
Prior art date
Application number
EA201391286A
Other languages
English (en)
Other versions
EA025180B1 (ru
Inventor
Стиг Линдер
Мортен Фрикнес
Рольф Ларссон
Original Assignee
Виволюкс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виволюкс Аб filed Critical Виволюкс Аб
Publication of EA201391286A1 publication Critical patent/EA201391286A1/ru
Publication of EA025180B1 publication Critical patent/EA025180B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Хелатор железа, способный проникать в клетку, возможно в комбинации с агентом, ингибирующим аутофагию, применяют для лечения солидной раковой опухоли у субъекта. Предпочтительный хелатор представляет собой замещенный алкилом N-(1-пиридин-2-илметилиден)-N-(9Н-1,3,4,9-тетраазафлуорен-2-ил)гидразин. Предпочтительный агент, ингибирующий аутофагию, представляет собой хлорохин. Также раскрыта фармацевтическая композиция, включающая хелатор железа, фармацевтически приемлемый носитель и, возможно, агент, ингибирующий аутофагию; и способ лечения рака путем введения эффективного(ных) для борьбы с раком количества (количеств) хелатора железа или комбинации хелатора железа и агента, ингибирующего аутофагию.
EA201391286A 2011-03-21 2012-03-14 Лечение солидных опухолей EA025180B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1100201 2011-03-21
PCT/SE2012/000034 WO2012128689A1 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Publications (2)

Publication Number Publication Date
EA201391286A1 true EA201391286A1 (ru) 2014-03-31
EA025180B1 EA025180B1 (ru) 2016-11-30

Family

ID=46879602

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391286A EA025180B1 (ru) 2011-03-21 2012-03-14 Лечение солидных опухолей

Country Status (20)

Country Link
US (2) US20140073645A1 (ru)
EP (1) EP2688569B1 (ru)
JP (1) JP6064215B2 (ru)
KR (1) KR101937279B1 (ru)
CN (1) CN103547268B (ru)
AU (1) AU2012231814B2 (ru)
BR (1) BR112013024211B1 (ru)
CA (1) CA2830081C (ru)
DK (1) DK2688569T3 (ru)
EA (1) EA025180B1 (ru)
ES (1) ES2681703T3 (ru)
HU (1) HUE039021T2 (ru)
IL (1) IL228411A (ru)
MX (1) MX2013010770A (ru)
PL (1) PL2688569T3 (ru)
PT (1) PT2688569T (ru)
SG (2) SG193494A1 (ru)
TR (1) TR201809040T4 (ru)
WO (1) WO2012128689A1 (ru)
ZA (1) ZA201307036B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102190768B1 (ko) * 2012-09-21 2020-12-14 비보룩스 아베 고형 종양의 치료 수단 및 방법
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN105807976B (zh) 2014-12-31 2019-02-12 清华大学 静电传感器
EP3283088A4 (en) * 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
CN104997777A (zh) * 2015-07-24 2015-10-28 孔小乐 去铁酮的2比1锌络合物作为制备抗癌药物的应用
JP7103745B2 (ja) * 2015-10-05 2022-07-20 国立大学法人 岡山大学 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
CN108431003A (zh) * 2015-12-18 2018-08-21 威沃路克斯股份公司 含有吲哚衍生物的药物组合物、其制备方法和用途
US20190358247A1 (en) * 2016-12-21 2019-11-28 The Medical College Of Wisconsin, Inc. Synergistic inihibition of tumor cell proliferation induced by combined treatment of metformin or metformin analogs and iron chelators
WO2018147612A1 (ko) * 2017-02-07 2018-08-16 주식회사 온코크로스 암의 전이 억제 및 치료용 조성물
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
CN106831776B (zh) * 2017-03-16 2018-12-07 河北科技大学 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用
EP3713573A1 (en) * 2017-11-23 2020-09-30 Deutsches Krebsforschungszentrum Iron chelators in tumor therapy
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN110585194A (zh) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用
CN111849873A (zh) * 2020-07-30 2020-10-30 扬州大学 一种诱导鸡的胚胎干细胞自噬的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335686C (fr) * 1986-01-13 1995-05-23 Rao K. S. P. Bhushana Vinblastine et composition pharmaceutique les contenant
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
DE602004031095D1 (de) * 2003-02-05 2011-03-03 David Benn Lovejoy Metallionenchelatoren und ihre therapeutische verwendung
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
JP2008520669A (ja) * 2004-11-19 2008-06-19 シバ バイオメディカル，エルエルシー エリスロポエチン抵抗性を治療する方法
JP2009536180A (ja) * 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
KR101208587B1 (ko) 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
KR102190768B1 (ko) 2012-09-21 2020-12-14 비보룩스 아베 고형 종양의 치료 수단 및 방법

Also Published As

Publication number Publication date
CN103547268B (zh) 2017-02-22
SG193494A1 (en) 2013-10-30
PL2688569T3 (pl) 2018-09-28
HUE039021T2 (hu) 2018-12-28
JP6064215B2 (ja) 2017-02-01
KR20140017619A (ko) 2014-02-11
US20140073645A1 (en) 2014-03-13
DK2688569T3 (en) 2018-08-06
CN103547268A (zh) 2014-01-29
MX2013010770A (es) 2014-03-27
JP2014508804A (ja) 2014-04-10
WO2012128689A1 (en) 2012-09-27
IL228411A0 (en) 2013-12-31
BR112013024211A2 (pt) 2016-12-20
US20170348317A1 (en) 2017-12-07
BR112013024211B1 (pt) 2020-12-15
ES2681703T3 (es) 2018-09-14
EP2688569A4 (en) 2014-09-10
AU2012231814A1 (en) 2013-09-26
CA2830081C (en) 2020-09-22
TR201809040T4 (tr) 2018-07-23
ZA201307036B (en) 2014-05-28
SG10201605083SA (en) 2016-08-30
CA2830081A1 (en) 2012-09-27
KR101937279B1 (ko) 2019-01-10
IL228411A (en) 2016-12-29
US10022380B2 (en) 2018-07-17
PT2688569T (pt) 2018-08-06
AU2012231814B2 (en) 2016-06-09
EA025180B1 (ru) 2016-11-30
EP2688569A1 (en) 2014-01-29
EP2688569B1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
EA201391286A1 (ru) Лечение солидных опухолей
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
ECSP10010589A (es) Farmaco contra el cancer de higado
PH12014501560A1 (en) Carbamate compounds and of making and using same
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
SG10201902664RA (en) Combination therapy for treating cancer
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
RU2012140185A (ru) Ингибирование ангиогенеза
EA201490254A1 (ru) Комбинированное лечение гепатита с
WO2016133903A3 (en) Combination therapy for cancer treatment
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
TW201613578A (en) Pharmaceutical combinations
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
ATE543492T1 (de) Behandlung von lungenkrebs
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM